Skip to content
10-Q

Quarterly Report

Acrivon Therapeutics, Inc. ACRV

0000950170-25-071427

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 31.36M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $110.48M
Short Term Investments Q1 2025 · Dec 31, 2024 $139.66M
Current Liabilities Q1 2025 · Mar 31, 2025 $13.55M
Current Liabilities Q1 2025 · Dec 31, 2024 $17.21M
Total Liabilities Q1 2025 · Mar 31, 2025 $15.96M
Total Liabilities Q1 2025 · Dec 31, 2024 $19.8M
Current Assets Q1 2025 · Mar 31, 2025 $151.33M
Current Assets Q1 2025 · Dec 31, 2024 $181.63M
Total Assets Q1 2025 · Mar 31, 2025 $176.35M
Total Assets Q1 2025 · Dec 31, 2024 $196.59M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $39.82M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $24.61M
Shares Diluted Q1 2025 · Mar 31, 2024 22.59M sh
Capex Q1 2025 · Mar 31, 2024 $815K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$17.08M
Stockholders Equity Q1 2025 · Mar 31, 2024 $107.98M
Stockholders Equity Q1 2025 · Dec 31, 2023 $121.2M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.73
Eps Basic Q1 2025 · Mar 31, 2024 −$0.73
Sga Expense Q1 2025 · Mar 31, 2024 $6.2M
Rd Expense Q1 2025 · Mar 31, 2024 $11.47M
Net Income Q1 2025 · Mar 31, 2024 −$16.49M
Operating Income Q1 2025 · Mar 31, 2024 −$17.67M